STANDIGM
Medical / Healthcare
STANDIGM
Medical / Healthcare
- Standigm ASK™ : artificial intelligence platform that provides a route that can interpret priorities.
- Standigm BEST™ : artificial intelligence platform that designs and optimizes new drug candidates for low-molecular-weight compounds
- SP001 : Best-in-class LRRK2 inhibitor of Parkinson’s Disease (PD)
- SP010 : First-in-class WRN inhibitor for
- Microsatellite instability (MSI) cance
- MP00103 : First-in-class TNIK inhibitor for LSCC(Lung squamous cell carcinoma), CRC(Colorectal cancer)
- MP00307 First-in-class PRKACA inhibitor for FL-HCC(Fibrolamellar carcinoma), ACC(Adrenocortical tumor), Cushing’s syndrome, HER2i-resistant breast cancer
- EP002 : First-in class selective DCLK1 inhibitor for Hepatocellular carcinoma (HCC)
https://www.standigm.com/
KANGSTEM BIOTECH
Medical / Healthcare
KANGSTEM BIOTECH
Medical / Healthcare
1. Furestem-AD®:
- First stem cell therapeutic product for atopic dermatitis that targets moderate to severe atopic dermatitis patients administered through Subcutaneous (SC) injection.
- MoA of Furestem-AD® is TGF-beta1 supresses the expression of FCE R1 receptor during the maturation of mast cells. Furestem-AD® secretes PGE2 and it supresses degranulation of mast cells. Furestem-AD® inhibits each step of mast cell activation and degranulation through the secretion of TGF-beta1 and PGE2
- Phase 3 is ongoing and aims to achieve product approval in 2024.
2. Furestem-OA Kit Inj.
- Composed of allogeneic umbilical cord blood-derived mesenchymal stem cells (Furestem-OA Inj.) as an active component, and cartilage acellular matrix (CAM Inj.) as a supportive material administered through Intra-articular (IA) injection and injected only once.
- MoA of Furestem-OA Kit Inj. is that In combintion of two components, the adinistered stem cells have the ability to differentiate into chondrocytes as well as being able to enhance inflamation moduation thus promoting osteoarthritic mitigation and cartilage regeneration.
- Phase 1 IND had been submitted and plans to proceed Phase 1 study during 2022.
3. Furestem-RA®
- Targets to treat the patients with moderat to severete rheumatoid arthritis through 3 repeated intravenous injection at 4 week intervals
- MoA of Furestem-RA® is that Furestem-RA® suppresses the activation of M1 macrophage, which induces inflammation, and induce generation of M2 macrophage. M2 macrophage suppress inflammatory symptoms and induce the regeneration of damaged tissues.
- Phase 1/2a was completed in March 2022 and the results are under review
http://www.kangstem.com/?lang=en
EVIDNET INC
Medical / Healthcare
EVIDNET INC
Medical / Healthcare
1.EVIX-Research
- EVIX-Research provides the end-to-end RWE service from protocol development to final report delivery
2. EVIX-Find
- EVIX-Find provides the service of target patients' eligibility at its partner hospital leveraging the EvidNet EMR data platform
3. EVIX-Insight
- Evix-Insight provides the new data insight from the clinical pathway with its effectiveness to patient journey utilizing its EMR data platform
https://en.evidnet.com
BIFIDO CO
Medical / Healthcare
BIFIDO CO
Medical / Healthcare
A research-driven company
- Founded by a team of scientists from Seoul National University, Korea, company founded in 1999
- Since then, BIFIDO has taken the lead in screening the best performing probiotics evidenced by human clinical trials.
- The efficacy of BIFIDO strains are backed by more than 250 scientific publications and 40 granted patents
- Three Bifidobacterium strains with GRAS and NDI notification by FDA
- Pharmabiotics piplines based on Microbiome
BIFIDO Express Platform: Integrated industrialization platform
- From the selection of pharmabiotics candidates to the production of finished products with various formulations. We make mutual profits through Express Platform-based collaboration.
S&K THERAPEUTICS
Medical / Healthcare
S&K THERAPEUTICS
Medical / Healthcare
Drugs for the treatment of autoimmune/inflammatory diseases
S&K Therapeutics is focusing its core capabilities on developing new small molecule drugs to meet the unmet medical needs, and aims to develop new medicine for systemic lupus erythematosus, psoriasis, rheumatoid arthritis, Alzheimer's disease, nonalcoholic steatohepatitis, multiple sclerosis, and diabetes.
http://www.snktherapeutics.com
AIGEN SCIENCE
Medical / Healthcare
AIGEN SCIENCE
Medical / Healthcare
1. Anti-cancer drug hit/lead compounds
- Hit/Lead compounds which inhibit KRAS::SOS1 protein-protein interaction
2. Cell-level transcriptome-based AI drug discovery platform
- Based on inference with cell-level transcriptome data and molecular modeling with target protein structure, AIGEN Science's AI platform technology is able to 1) discover potential hit compounds from billion-scale library and develop new drug candidates to target indication through de novo design and multi-parameter optimization, 2) secure effective compounds and identify an actual target and/or mode of action when target information is unknown, and, therefore, 3) be widely applied to innovative drug discovery, drug repurposing, and also novel target discovery
www.aigensciences.com
TEGO SCHIENCE
Medical / Healthcare
TEGO SCHIENCE
Medical / Healthcare
1. Holoderm
- Holoderm is an autologous cultured skin graft. It is indicated to treat 3rd degree burns and fully reimbursed under Korean Industrial Accident Compensation Insurance. This cultured skin autograft can be used to treat burn scars, vitiligo, and giant cong
2. Kaloderm
- Kaloderm is an allogeneic cultured skin graft that is manufactured from Tego’s KFDA-approved skin banking system, SkinBank®. It is indicated to treat deep 2nd degree burns and diabetic foot ulcers. It is reimbursed by the Korean National Health Insurance
3. Rosmir
- Rosmir is an injectable autologous fibroblast cell therapy. It is indicated for treatment of nasojugal grooves (a.k.a. tear trough). It can be used for various wrinkle augmentations.
https://www.tegoscience.com
APRILBIO CO
Medical / Healthcare
APRILBIO CO
Medical / Healthcare
AprilBio Co., Ltd. (AprilBio) is a bio-tech company specialized in development of novel bio-therapeutics by utilizing two platform technologies — SAFA (anti-Serum Albumin Fab-Associated): serum half-life (T1/2) extension technology; and Naive human antibody (Fab fragment) library: source of antibody candidates — for the treatment of autoimmune and cancer diseases.
RUDACURE
Medical / Healthcare
RUDACURE
Medical / Healthcare
RudaCure is a 4 year old bio start-up company founded with the vision to solve current unmet needs for incurable disease by developing effective and superior treatments to make a painless world. RudaCure focuses on developing treatments for sensory specific diseases, and are currently developing ophthalmic treatments for Dry Eye Disease and AMD. RudaCure is also developing a non-opioid treatment for chronic pain. Besides clinical development, RudaCure also provides CRO services such as electrophysiological studies and efficacy tests on animal models.
DT&SANO MEDICS
Medical / Healthcare
DT&SANO MEDICS
Medical / Healthcare
Service (Clinical Trial Consulting and Project Management)
1) RA (Regulatory Affairs)
- Regulatory and Market Access Strategies
- Product Registrations
- Regulatory Dossier Packaging (CTD Packaging)
- IB Writing
- Gap Analysis
- Orphan Drug Designation
- CE Registration
2) MW (Medical Writing)
- Protocol, Synopsis Writing
- CSR Writing
- Clinical development consulting
- Medical monitoring for clinical trial
- Medical Consulting
- Publication
- Manuscript Writing
3) PV (Pharmacovigilance)
- Medical Assessment of adverse event
- Trending Assessment
- IDMC Preparation and Management
- DSMB Preparation and Management
- PV Writing: PUSR, DSUR, RMP Writing
- PharmacoEconomics (Medical Support for Pricing and Reimbursement)
4) CO (Clinical Operation)
- Project Management
- Site and Investigator Feasibility
- IRB Affairs
- Study and Site Monitoring Start Up/PSV,SIV,RMV,COV
- Trial Management File
- Risk Based Monitoring
5) DM (Data Management)
- Data Management
- Design/Development of CRFs
- EDC Set-up
- Data Validation
- Medical Coding
- SAE Reconciliation
- External Data Handling
- Data Quality Control
- Data Matrix
- Dedicated DM
6) STAT (Statistics)
- Statistical Consulting and Design
- Protocol and Statistical Analysis Plan
- Sample Size and Power Estimation
- Randomization
- Interim and Final Statistical Analysis
- Interpretation, Writing
- Review of Clinical Study Reports
www.dtnsm.co.kr
IMBDX
Medical / Healthcare
IMBDX
Medical / Healthcare
AlphaLiquid®100
AlphaLiquid®100 is a minimally invasive Comprehensive Genomic Profiling (CGP) test for patients with advanced solid cancer. With a single collection of blood, it tests for genetic alterations in 118 cancer-related genes and offers FDA-approved therapy options for physicians to make a better clinical decision. Using our proprietary, AI-driven bioinformatics, the result report is delivered within 2 weeks from sample arrival.
www.imbdx.com
DIGIRAY
Medical / Healthcare
DIGIRAY
Medical / Healthcare
Dental CR Imaging System
The FireCR Dental Reader is a compact and affordable Computed Radiography PSP system for dental professionals. It is designed to provide fast, high-quality reading of reusable dental imaging plates, enabling better patient care. With its small footprint, the reader fits seamlessly into even the most space-challenged dental offices and exam rooms.
LSK GLOBAL SERVICE PHARMA
Medical / Healthcare
LSK GLOBAL SERVICE PHARMA
Medical / Healthcare
Product development/Clinical trial strategy consulting, Project Management, Clinical Operation, Data Management, Biostatistics, Medical Writing (Clinical trial design development and Clinical study report writing), Medical Service consulting for new drug or new technology TPP/clinical strategy/safety and efficacy evaluation, regulatory authority submissions/affairs handling by regulatory specialists, post marketing surveillance (prospective/retrospective) trials, quality assurance/inspection ready support
LSK Global PS, the first Korean CRO to acquire the ISO 9001:2015 certification for Quality Management Systems in all areas of our services, is the first local CRO that has conducted more than 130 global clinical trials and completed a large scale multinational clinical trial at more than 95 sites in 12 countries including the US, Europe, and Asia.
The excellence and quality data provided by LSK Global PS for conducting clinical trials has been verified with domestic and global audits by pharmaceutical companies, global CROs, and inspections by the Korea Ministry of Food and Drug Safety (MFDS).
http://www.lskglobal.com
JD BIOSCIENCES
Medical / Healthcare
JD BIOSCIENCES
Medical / Healthcare
GM-60106, Novel Drug Candidate for Non-alcoholic Steatohepatitis (NASH)
GM-60106 is a first-in-class drug candidate for NASH.
GM-60106 blocks the novel target 5-hydroxytryptamine receptor 2A (HTR2A) that is directly connected to fibrosis and correlated steatosis.
Preclinical and toxicology studies were completed and showed that the compound can improve both hepatosteatosis and liver fibrosis and is not permeable to blood-brain barrier (BBB); thus, it does not induce any CNS-mediated side effects.
A clinical study is planned for Q3 of 2022 in Australia to assess the safety, tolerability, and pharmacokinetics of GM60106
www.jdbiosci.com
BIO3S
Medical / Healthcare
BIO3S
Medical / Healthcare
Beanguard Plus
- Original technology for jack bean-derived antiviral protein for elimination and neutralization of respiratory viruses attached to the oral cavity
- Completed clinical trial for rapid diagnosis of coronavirus using mouthwash gargle